Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 1/20 | 0.41 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28529 | 0.98 | FDPS (0.42) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL28659170 | 0.96 | FDPS (0.41) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL671498 | 0.96 | FDPS (0.41) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| Tetrahydrofuran SCHEMBL28855131 | 0.84 | FDPS (0.35) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| Malonic Acid SCHEMBL28513650 | 0.83 | HDAC1 (0.44) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL28340215 | 0.74 | FDPS (0.44) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL7787139 | 0.72 | FDPS (0.42) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL10664500 | 0.72 | FDPS (0.46) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL30341176 | 0.72 | GRM5 (0.46) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL5633 | 0.72 | FDPS (0.42) | FDPSHDAC1HDAC6LTA4HCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411039-B1 | MERCAPTOPURINE HEMIHYDRATE | UNIV MICHIGAN REGENTS (US) | 2020-06-24 | — | — | EP | claimed |
| US-10590137-B2 | Mercaptopurine hemihydrate | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-03-17 | — | — | US | claimed |
| US-20190048010-A1 | Mercaptopurine Hemihydrate | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-14 | — | — | US | claimed |
| EP-3411039-A1 | MERCAPTOPURINE HEMIHYDRATE | The Regents of The University of Michigan (US) | 2018-12-12 | — | — | EP | claimed |
| WO-2017136488-A1 | MERCAPTOPURINE HEMIHYDRATE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-10 | — | — | WO | claimed |
| US-7901453-B2 | Coated implantable medical device | COOK INCORPORATED (US) | 2011-03-08 | — | — | US | claimed |
| US-20080145399-A1 | coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer | COOK MEDICAL TECHNOLOGIES LLC | 2008-06-19 | — | — | US | claimed |
| US-20080145398-A1 | coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | claimed |
| US-20030036794-A1 | Coated implantable medical device | COOK INCORPORATED | 2003-02-20 | — | — | US | claimed |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3411039-B1 | MERCAPTOPURINE HEMIHYDRATE | UNIV MICHIGAN REGENTS (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10590137-B2 | Mercaptopurine hemihydrate | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3029041-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10575972-B2 | Medical device with induction triggered anchors and system for deployment of the same | COOK MEDICAL TECHNOLOGIES LLC (US) | 2020-03-03 | — | — | US | disclosed |
| WO-2003035075-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-05-01 | — | — | WO | disclosed |
| US-20030036794-A1 | Coated implantable medical device | COOK INCORPORATED | 2003-02-20 | — | — | US | disclosed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1278748-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | disclosed |
| WO-2001081346-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | FDPS 2780/4885HDAC1 1833/4885HDAC6 2844/4885 |
| US-10590137-B2 | Mercaptopurine hemihydrate | TPMT, MTHFD2, MSH2 | FDPS 381/4885HDAC1 2885/4885HDAC6 2164/4885 |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | FDPS 3023/4885HDAC1 897/4885HDAC6 1189/4885 |
| US-20190048010-A1 | Mercaptopurine Hemihydrate | TPMT, MTHFD2, MSH2 | FDPS 381/4885HDAC1 2885/4885HDAC6 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.